C-Path's Transplant Therapeutics Consortium Letter of Intent accepted by FDA

(Critical Path Institute (C-Path)) Critical Path Institute (C-Path) announced today that its Transplant Therapeutics Consortium (TTC) has received a positive response to its Letter of Intent (LOI) from the US Food and Drug Administration (FDA) detailing the decision to accept the Composite Biomarker Panel (iBox Scoring System) into the Center for Drug Evaluation and Research (CDER) Biomarker Qualification Program (BQP).
Source: EurekAlert! - Social and Behavioral Science - Category: International Medicine & Public Health Source Type: news